Skip to main content
Susan Blaney, MD, Pediatric Hematology & Oncology, Houston, TX, Texas Children's Hospital

SusanBlaneyMD

Pediatric Hematology & Oncology Houston, TX

Director, Texas Children’s Cancer and Hematology Center

Dr. Blaney is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Blaney's full profile

Already have an account?

Summary

  • Dr. Susan Blaney holds the David G. Poplack, M.D. Chair of Pediatric Hematology-Oncology at Texas Children's Hospital and the Elise C. Young Chair of Pediatric Oncology at Baylor College of Medicine. She is also the Director of Texas Children's Cancer and Hematology Center and Division Chief of Pediatric Hematology/Oncology for Baylor College of Medicine. She was the Vice Chair of the Children's Oncology Group (COG) from 2013-2020.

    Previously, Dr. Blaney served in various roles at Baylor College of Medicine, including Vice President for Clinical and Translational Research, Executive Vice Chair of the Department of Pediatrics, and founding director of the Dan L. Duncan Institute for Clinical and Translational Research (ICTR), among others.

    Her career, spanning over 25 years, is dedicated to improving therapeutic strategies for children with recurrent or refractory cancer, especially malignancies of the central nervous system. She has participated in the development of numerous clinical trials of novel agents for the treatment of childhood cancer.

    Dr. Blaney has been a mentor to many in the field of pediatric oncology and has served on various advisory and membership roles, including the NCI’s Clinical Trial Advisory and Investigational Drug Steering Committees, FDA’s Pediatric Oncology Drug Advisory Committee, and more.

    She has received numerous awards and has published over 200 articles in peer-reviewed journals. She also co-edits Rudolph’s Pediatrics and Pizzo and Poplack’s Pediatric Oncology.

Education & Training

  • National Capital Consortium
    National Capital ConsortiumFellowship, Pediatric Hematology/Oncology, 1987 - 1990
  • Letterman Army Medical Center
    Letterman Army Medical CenterResidency, Pediatrics, 1985 - 1987
  • Tripler Army Medical Center
    Tripler Army Medical CenterInternship, Transitional Year, 1984 - 1985
  • The University of Toledo College of Medicine
    The University of Toledo College of MedicineClass of 1984

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1995 - 2025
  • MD State Medical License
    MD State Medical License 1988 - 1992
  • CA State Medical License
    CA State Medical License 1986 - 1988
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • Medical Honoree American Cancer Society; Houston, TX, 2023
  • The David G. Poplack MD Chair in Pediatric Oncology Texas Children's Hospital, 2021
  • Women of Excellence Award Baylor College of Medicine, 2019
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A phase 1 trial of cixutumumab (IMC-A12) in combination with temsirolimus (CCI-779) in children with recurrent solid tumors: a Children’s Oncology Group Phase 1 Consor...  
    Fouladi, M., Perentesis, J.P., Wagner, L.M., Vinks, A.A., Reid, J., Ingle, A.M., Thomas, G., Krueger, D.A., Houston, P., Doyle, L.A., Weigel, B., Blaney, S.M., Clin Cancer Research, 1/1/2014
  • Phase 1 trial of Seneca Valley virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children’s Oncology Group  
    Burke, M.J., Ahern, C., Weigel, B.J., Poirier, J.T., Rudin, C., Chen, Y., Cripe, R., Bernhardt, M.B., Blaney, S.M., Ped Blood and Cancer, 1/1/2014
  • A phase 1 trial and pharmacokinetic study of the raf kinase and receptor tyrosine kinase inhibitor, sorafenib, in children with refractory solid tumors or refractory l...  
    Widemann, B.C., Kim, A., Fox, E., Baruchel, S., Adamson, P.C., Ingle, A.M., Bender, J.G., Burke, M., Weigel, B., Stempak, D., Balis, F.M., Blaney, S.M., Clin Cancer Res, 1/1/2012
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • A phase 1 study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: a Children’s Oncology Group Phase ...
    Chuk, M., Widemann, B., Ahern, C., Reid, J., Fox, E., Weigel, B., Blaney, S.M., ASCO, 1/1/2014
  • A phase II study of cixutumumab in combination with temsirolimus in pediatric patients with recurrent or refractory solid tumors: a report from the Children’s Oncology...
    Wagner, L.M., Fouladi, M., Ahmed, A., Krailo, M.D., Weigel, B., DuBois, S., Doyle, L.A., Chen, H., Blaney, S.M., ASCO, 1/1/2014
  • A phase 2 study of the c-Met inhibitor, tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: a Children’s Oncology Group study.
    Geller, J.I., Perentesis, J.P., Ahern, C.H., Reid, J.M., Fox, E., Blaney, S.M., Weigel, B.J., ASCO, 1/1/2014
  • Join now to see all

Lectures

  • Introduction to Pediatric CNS Tumors 
    Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX - 1/1/2014
  • Oncologic Emergencies 
    Texas Children’s Hospital, Houston, TX - 1/1/2014
  • Introduction to Chemotherapy 
    Texas Children’s Hospital, Houston, TX - 1/1/2014
  • Join now to see all

Press Mentions

  • Dr. Michael Taylor Joins Texas Children’s Hospital and Baylor College of Medicine as Director of the Pediatric Neuro-Oncology Research Program
    Dr. Michael Taylor Joins Texas Children’s Hospital and Baylor College of Medicine as Director of the Pediatric Neuro-Oncology Research ProgramFebruary 8th, 2023
  • Film Available on YouTube Shines Light on Childhood Cancer
    Film Available on YouTube Shines Light on Childhood CancerSeptember 10th, 2020
  • Grand Opening Set for Halo House’s 33-Unit Facility for Cancer Patients
    Grand Opening Set for Halo House’s 33-Unit Facility for Cancer PatientsMay 2nd, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations